ESR1 and breast carcinoma: Endocrine therapies related to anti-estrogen signals for ER-positive breast cancer can be classified into those that target estrogen receptors and those that target estrogen synthesis based on their different mechanisms of action (Burstein2019, Rej et al. 2024).